Evidence map›Paper›PMID 35736350›Full record

ArticleMedical sciences (Basel, Switzerland)2022

The Incidence of Venous Thromboembolism in Critically Ill Patients with SARS-CoV-2 Infection Compared with Critically Ill Influenza and Community-Acquired Pneumonia Patients: A Retrospective Chart Review.

Sean Boyd, Kai Sheng Loh, Jessie Lynch, Dhari Alrashed, Saad Muzzammil, Hannah Marsh, Mustafa Masoud, Salman Bin Ihsan, Ignacio Martin-Loeches

Abstract read
In one paragraph

Article in Medical sciences (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sean BoydMultidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, D08 NHY1 Dublin, Ireland.
Kai Sheng LohMultidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, D08 NHY1 Dublin, Ireland.
Jessie LynchMultidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, D08 NHY1 Dublin, Ireland.
Dhari AlrashedMultidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, D08 NHY1 Dublin, Ireland.ORCID 0000-0002-7108-0082
Saad MuzzammilMultidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, D08 NHY1 Dublin, Ireland.
Hannah MarshMultidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, D08 NHY1 Dublin, Ireland.
Mustafa MasoudMultidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, D08 NHY1 Dublin, Ireland.
Salman Bin IhsanMultidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, D08 NHY1 Dublin, Ireland.
Ignacio Martin-LoechesMultidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, D08 NHY1 Dublin, Ireland.ORCID 0000-0002-5834-4063

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rate of venous thromboembolism in COVID-19 patients has been reported to be 30% (deep vein thrombosis 20% and pulmonary embolism 18%). This has been shown to be higher in COVID-19 patients admitted to the ICU. Prophylactic anticoagulation may be sufficient at ward level, but not in intensive care. A retrospective chart review was undertaken in a large university hospital. The review included 276 patients from COVID-19 Wave 1, COVID-19 Wave 2, influenza, and community-acquired pneumonia groups. The timeframe included patients admitted between 23 February 2014 and 12 May 2021. Clinical characteristics, outcomes, blood results, rates of venous thromboembolism, and anticoagulation status were recorded. The incidence of venous thromboembolism in COVID-19 Wave 1, COVID-19 Wave 2, influenza, and community-acquired pneumonia was 10.91%, 13.69%, 13.33%, and 6.81%, respectively (

Indexed as

COVID-19Influenza, HumanPulmonary EmbolismVenous ThromboembolismVenous ThrombosisAnticoagulantsCritical IllnessHumansIncidenceRetrospective StudiesSARS-CoV-2Anticoagulantscommunity-acquired pneumoniaCOVID-19DVT (deep vein thrombosis)ICU (intensive care unit)influenzaPE (pulmonary embolism)VTE (venous thromboembolism)

Identifiers

PMID35736350
PMCPMC9231025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.